$NAOV
NanoVibronix, Inc. Stock $naov

$naov Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000149315224013966 Filed on April 08, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$817.0K	$1.177M	$2.283M
YoY Change	177.89%	56.52%	203.59%
Cost Of Revenue	$389.0K	$440.0K	$746.0K
YoY Change	398.72%	-24.79%	27.52%
Gross Profit	$428.0K	$737.0K	$1.537M
YoY Change	98.15%	341.32%	820.36%
Gross Profit Margin	52.39%	62.62%	67.32%
Selling, General & Admin	$915.0K	$1.377M	$4.788M
YoY Change	-23.11%	-71.88%	-2.21%
% of Gross Profit	213.79%	186.84%	311.52%
Research & Development	$187.0K	$62.00K	$185.0K
YoY Change	434.29%	-78.09%	-34.63%
% of Gross Profit	43.69%	8.41%	12.04%
Depreciation & Amortization	$1.000K	$1.000K	$1.000K
YoY Change			0.0%
% of Gross Profit	0.23%	0.14%	0.07%
Operating Expenses	$1.102M	$1.439M	$4.973M
YoY Change	-10.04%	-72.21%	-3.98%
Operating Profit	-$674.0K	-$702.0K	-$3.436M
YoY Change	-33.2%	-85.99%	-31.44%
Interest Expense	$34.00K	-$100.0K	-$246.0K
YoY Change	3.03%	-75.06%	-170.89%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$684.0K	-$802.0K	-$3.682M
YoY Change	-35.53%	-85.18%	-31.98%
Income Tax	$4.000K	$11.00K	$29.00K
% Of Pretax Income
Net Earnings	-$688.0K	-$813.0K	-$3.711M
YoY Change	-237.6%	-85.08%	-31.88%
Net Earnings / Revenue	-84.21%	-69.07%	-162.55%
Basic Earnings Per Share	-$0.25		-$2.12
Diluted Earnings Per Share	-$0.25	-$0.41	-$2.12
COMMON SHARES
Basic Shares Outstanding	2.784M shares	2.046M shares	1.750M shares
Diluted Shares Outstanding	2.784M shares		1.750M shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.170M	$3.283M	$3.283M
YoY Change	757.71%	21.01%	21.01%
Cash & Equivalents	$2.170M	$3.283M
Short-Term Investments
Other Short-Term Assets	$296.0K	$154.0K	$47.00K
YoY Change	68.18%	54.0%	-92.32%
Inventory	$2.431M	$2.732M	$2.732M
Prepaid Expenses		$47.00M
Receivables	$489.0K	$318.0K	$318.0K
Other Receivables	$0.00	$0.00	$107.0K
Total Short-Term Assets	$5.386M	$6.487M	$6.487M
YoY Change	49.03%	15.65%	15.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.000K	$12.00K	$12.00K
YoY Change	28.57%	71.43%	-86.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.000K	$175.0K	$175.0K
YoY Change	-66.67%	5733.33%	-3.85%
Total Long-Term Assets	$310.0K	$187.0K	$187.0K
YoY Change	42.86%	-30.74%	-30.74%
TOTAL ASSETS
Total Short-Term Assets	$5.386M	$6.487M	$6.487M
Total Long-Term Assets	$310.0K	$187.0K	$187.0K
Total Assets	$5.696M	$6.674M	$6.674M
YoY Change	48.68%	13.52%	13.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$92.00K	$138.0K	$138.0K
YoY Change	178.79%	109.09%	109.09%
Accrued Expenses	$44.00K	$5.000K	$5.000K
YoY Change	18.92%	-93.83%	-93.83%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.556M	$2.454M	$2.454M
YoY Change	7.85%	5.96%	5.96%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$299.0K	$232.0K	$232.0K
YoY Change	1.01%	-29.7%	-29.7%
Total Long-Term Liabilities	$299.0K	$232.0K	$232.0K
YoY Change	1.01%	-29.7%	-29.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.556M	$2.454M	$2.454M
Total Long-Term Liabilities	$299.0K	$232.0K	$232.0K
Total Liabilities	$2.855M	$2.686M	$2.686M
YoY Change	7.09%	1.51%	1.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$67.37M	-$66.10M
YoY Change	4.36%	5.95%
Common Stock	$2.000K	$2.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.841M	$3.988M	$3.988M
YoY Change
Total Liabilities & Shareholders Equity	$5.696M	$6.674M	$6.674M
YoY Change	48.68%	13.52%	13.52%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$688.0K	-$813.0K	-$3.711M
YoY Change	-237.6%	-85.08%	-31.88%
Depreciation, Depletion And Amortization	$1.000K	$1.000K	$1.000K
YoY Change			0.0%
Cash From Operating Activities	-$553.0K	-$492.0K	-$3.602M
YoY Change	-55.0%	-63.04%	-48.8%
INVESTING ACTIVITIES
Capital Expenditures	$2.000K	$1.000K	$1.000K
YoY Change		-200.0%	-66.67%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$2.000K	-$1.000K	-$1.000K
YoY Change		-200.0%	-66.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$4.222M
YoY Change			102.01%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	28.00K	2.000K	4.222M
YoY Change		-99.9%	101.82%
NET CHANGE
Cash From Operating Activities	-553.0K	-492.0K	-3.602M
Cash From Investing Activities	-2.000K	-1.000K	-1.000K
Cash From Financing Activities	28.00K	2.000K	4.222M
Net Change In Cash	-527.0K	-491.0K	619.0K
YoY Change	-57.12%	-164.44%	-112.32%
FREE CASH FLOW
Cash From Operating Activities	-$553.0K	-$492.0K	-$3.602M
Capital Expenditures	$2.000K	$1.000K	$1.000K
Free Cash Flow	-$555.0K	-$493.0K	-$3.603M
YoY Change	-54.84%	-62.93%	-48.81%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001326706
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	NAOV	Issuance Of Redeemable Series F Preferred Stock IssuanceOfRedeemableSeriesFPreferredStock		usd
CY2022	NAOV	Redemption Of Redeemable Series F Preferred Stock RedemptionOfRedeemableSeriesFPreferredStock		usd
CY2023	NAOV	Stock Issued During Period Value Prefunded Warrants Exercised StockIssuedDuringPeriodValuePrefundedWarrantsExercised		usd
CY2023	NAOV	Stock Issued During Period Values Reverse Stock Splits StockIssuedDuringPeriodValuesReverseStockSplits		shares
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023	NAOV	Exchange Of Common Stocks Into Preferred Stock ExchangeOfCommonStocksIntoPreferredStock		usd
CY2022	NAOV	Exchange Of Common Stocks Into Preferred Stock ExchangeOfCommonStocksIntoPreferredStock		usd
CY2023	NAOV	Shares Issued From Exercise Of Warrants Previously Classified As Derivative Liability SharesIssuedFromExerciseOfWarrantsPreviouslyClassifiedAsDerivativeLiability		usd
CY2022	NAOV	Shares Issued From Exercise Of Warrants Previously Classified As Derivative Liability SharesIssuedFromExerciseOfWarrantsPreviouslyClassifiedAsDerivativeLiability		usd
CY2023	NAOV	Reclass Derivative Liability To Equity Due To Increase In Authorized Shares ReclassDerivativeLiabilityToEquityDueToIncreaseInAuthorizedShares		usd
CY2022	NAOV	Reclass Derivative Liability To Equity Due To Increase In Authorized Shares ReclassDerivativeLiabilityToEquityDueToIncreaseInAuthorizedShares		usd
CY2023	NAOV	Reclass Liability To Equity After Increase In Authorized Shares ReclassLiabilityToEquityAfterIncreaseInAuthorizedShares		usd
CY2022	NAOV	Reclass Liability To Equity After Increase In Authorized Shares ReclassLiabilityToEquityAfterIncreaseInAuthorizedShares		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	138000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	66000	usd
CY2023Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	2265000	usd
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	4830581	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2784354	shares
CY2023	dei	Auditor Firm AuditorFirmId	549
CY2022	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Zwick CPA, PLLC
CY2023	dei	Auditor Location AuditorLocation	Southfield, Michigan
CY2022	dei	Auditor Name AuditorName	Marcum LLP
CY2022	dei	Auditor Location AuditorLocation	New York, NY
CY2023Q4	us-gaap	Cash Cash	3283000	usd
CY2022Q4	us-gaap	Cash Cash	2713000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	318000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	154000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	712000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2732000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	2175000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	6487000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	5609000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3000	usd
CY2023Q4	NAOV	Severance Assets Noncurent SeveranceAssetsNoncurent	174000	usd
CY2022Q4	NAOV	Severance Assets Noncurent SeveranceAssetsNoncurent	179000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	81000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	187000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	270000	usd
CY2023Q4	us-gaap	Assets Assets	6674000	usd
CY2022Q4	us-gaap	Assets Assets	5879000	usd
CY2022Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	2148000	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	46000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	21000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	81000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2454000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2316000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	217000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	223000	usd
CY2023Q4	us-gaap	Deferred Income Noncurrent DeferredIncomeNoncurrent	15000	usd
CY2022Q4	us-gaap	Deferred Income Noncurrent DeferredIncomeNoncurrent	107000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2686000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2646000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2046307	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2046307	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1641146	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1641146	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	70149000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	65634000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-67000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-18000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-66096000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-62385000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3988000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3233000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6674000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5879000	usd
CY2023	us-gaap	Gross Profit GrossProfit	1537000	usd
CY2022	us-gaap	Gross Profit GrossProfit	167000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	864000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3924000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3931000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	4973000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	5179000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-3436000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-5012000	usd
CY2023	us-gaap	Interest Expense InterestExpense	135000	usd
CY2022	us-gaap	Interest Expense InterestExpense	347000	usd
CY2023	NAOV	Financial Expenses Net FinancialExpensesNet	-111000	usd
CY2022	NAOV	Financial Expenses Net FinancialExpensesNet	-54000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3682000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5413000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	35000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3711000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5448000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.12
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.12
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.84
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.84
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1750109	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1750109	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1419670	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1419670	shares
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3711000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5448000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	49000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	78000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3760000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5526000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	6313000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	190000	usd
CY2022	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	310424000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2090000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-78000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5448000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3233000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3233000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	293000	usd
CY2023	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	785084000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4215000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-49000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3711000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3988000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3988000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3711000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	293000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	354000	usd
CY2023	NAOV	Noncash Interest Expense NoncashInterestExpense	135000	usd
CY2022	NAOV	Noncash Interest Expense NoncashInterestExpense	347000	usd
CY2023	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-2000	usd
CY2022	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-16000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	309000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-191000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-558000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	482000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	557000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2000000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	72000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-21000	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-18000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	78000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-67000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-69000	usd
CY2023	NAOV	Increase Decrease In Accrued Severance Pay Net IncreaseDecreaseInAccruedSeverancePayNet	-1000	usd
CY2022	NAOV	Increase Decrease In Accrued Severance Pay Net IncreaseDecreaseInAccruedSeverancePayNet	-2000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3602000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7035000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4215000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2090000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4222000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2092000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-49000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-78000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	570000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5024000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2713000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7737000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3283000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2713000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_805_eus-gaap--NatureOfOperations_zJtWRxkiuXu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - <span id="xdx_828_zCqAWYceMhu1">DESCRIPTION OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoVibronix, Inc. (the “Company”), a Delaware corporation, commenced operations on October 20, 2003, and is a medical device company focusing on non-invasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without the assistance of medical professionals.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s principal research and development activities are conducted in Israel through its wholly-owned subsidiary, NanoVibronix Ltd., a company registered in Israel, which commenced operations in October 2003.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3602000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4215000	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	785000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zrtOcbK35hEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zuPYMrFWIMHa">Use of estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	49000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	85	usd
CY2023Q4	us-gaap	Inventory Adjustments InventoryAdjustments	0	usd
CY2022Q4	us-gaap	Inventory Adjustments InventoryAdjustments	0	usd
CY2023	us-gaap	Severance Costs1 SeveranceCosts1	217000	usd
CY2022	us-gaap	Severance Costs1 SeveranceCosts1	223	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	47000000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	612000000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	107000000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	100000000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	154000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	712000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	210000000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	30000000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2522000000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2145000000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2732000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	2175000	usd
CY2023Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-20 Reverse Stock Split
CY2023Q1	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	15726	shares
CY2023	NAOV	Share Based Compensation Arrangement By Share Based Payment Award Contractual Period ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod	P10Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q4	us-gaap	Share Price SharePrice	1.15
CY2022Q4	us-gaap	Share Price SharePrice	5.04
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0383	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0442	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0232	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0358	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.331	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.336	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.253	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.279	pure
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	292000000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	354000000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	292000000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	354000000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	123000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P0Y11M19D
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	12500	shares
CY2022Q2	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2029-06-14
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	20.00
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	135000000	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	12500	shares
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	135000	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	18000	shares
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y3M
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	70000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6000000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6000000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1000000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5000000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8745915	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	225871	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8745915	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	225871	shares
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2283000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	752000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2283000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	752000	usd
CY2023Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	1000	usd
CY2022Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	3000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	16000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3000	usd
CY2021Q1	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	3000000	usd
CY2022Q1	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	1500250	usd
CY2022Q1	us-gaap	Loss Contingency Damages Awarded Value LossContingencyDamagesAwardedValue	1432000	usd
CY2022Q1	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	68250	usd
CY2023	us-gaap	Legal Fees LegalFees	360000	usd
CY2023Q4	NAOV	Federal Net Operating Loss Carried Forward FederalNetOperatingLossCarriedForward	24600000	usd
CY2023	NAOV	Federal Net Operating Loss Offset Against Taxable Income FederalNetOperatingLossOffsetAgainstTaxableIncome	14000000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-25000000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	37000000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-25000000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	37000000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1226000000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1545000000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-43000000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	653000000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	2000000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1000000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1267000000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-893000000	usd
CY2023	NAOV	Valuation Allowance Of Income Tax Expense Benefit ValuationAllowanceOfIncomeTaxExpenseBenefit	-1267000000	usd
CY2022	NAOV	Valuation Allowance Of Income Tax Expense Benefit ValuationAllowanceOfIncomeTaxExpenseBenefit	-893000000	usd
CY2023	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	-25000000	usd
CY2022	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	37000000	usd
CY2023	NAOV	Franchise Fees FranchiseFees	4000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0113	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.1206	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0010	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0003	pure
CY2023	NAOV	Effective Income Tax Rate Reconciliation Permanent Items EffectiveIncomeTaxRateReconciliationPermanentItems	-0.0063	pure
CY2022	NAOV	Effective Income Tax Rate Reconciliation Permanent Items EffectiveIncomeTaxRateReconciliationPermanentItems	-0.0061	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3354	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1661	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.1220	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.0754	pure
CY2023	NAOV	Effective Income Tax Rate Reconciliation Forfeited Options EffectiveIncomeTaxRateReconciliationForfeitedOptions	0.0000	pure
CY2022	NAOV	Effective Income Tax Rate Reconciliation Forfeited Options EffectiveIncomeTaxRateReconciliationForfeitedOptions	0.0000	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0001	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0009	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0006	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0068	pure
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	3785000000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	5557000000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	103000000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	144000000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3682000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5413000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8486000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7306000000	usd
CY2023Q4	NAOV	Deferred Tax Assets Tax Deferred Expense Accruals DeferredTaxAssetsTaxDeferredExpenseAccruals	414000000	usd
CY2022Q4	NAOV	Deferred Tax Assets Tax Deferred Expense Accruals DeferredTaxAssetsTaxDeferredExpenseAccruals	414000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther	570000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther	483000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	9470000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8203000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9470000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8203000000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1267000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	894000	usd

Files In Submission

Name	View Source	Status
0001493152-24-013966-index-headers.html	Edgar Link	pending
0001493152-24-013966-index.html	Edgar Link	pending
0001493152-24-013966.txt	Edgar Link	pending
0001493152-24-013966-xbrl.zip	Edgar Link	pending
ex10-75.htm	Edgar Link	pending
ex10-76.htm	Edgar Link	pending
ex1_001.jpg	Edgar Link	pending
ex1_002.jpg	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex23-2.htm	Edgar Link	pending
ex2_001.jpg	Edgar Link	pending
ex2_002.jpg	Edgar Link	pending
ex2_003.jpg	Edgar Link	pending
ex2_004.jpg	Edgar Link	pending
ex2_005.jpg	Edgar Link	pending
ex2_006.jpg	Edgar Link	pending
ex2_007.jpg	Edgar Link	pending
ex2_008.jpg	Edgar Link	pending
ex2_009.jpg	Edgar Link	pending
ex2_010.jpg	Edgar Link	pending
ex2_011.jpg	Edgar Link	pending
ex2_012.jpg	Edgar Link	pending
ex2_013.jpg	Edgar Link	pending
ex2_014.jpg	Edgar Link	pending
ex2_015.jpg	Edgar Link	pending
ex2_016.jpg	Edgar Link	pending
ex2_017.jpg	Edgar Link	pending
ex2_018.jpg	Edgar Link	pending
ex2_019.jpg	Edgar Link	pending
ex2_020.jpg	Edgar Link	pending
ex2_021.jpg	Edgar Link	pending
ex2_022.jpg	Edgar Link	pending
ex2_023.jpg	Edgar Link	pending
ex2_024.jpg	Edgar Link	pending
ex2_025.jpg	Edgar Link	pending
ex2_026.jpg	Edgar Link	pending
ex2_027.jpg	Edgar Link	pending
ex2_028.jpg	Edgar Link	pending
ex2_029.jpg	Edgar Link	pending
ex2_030.jpg	Edgar Link	pending
ex2_031.jpg	Edgar Link	pending
ex2_032.jpg	Edgar Link	pending
ex2_033.jpg	Edgar Link	pending
ex2_034.jpg	Edgar Link	pending
ex2_035.jpg	Edgar Link	pending
ex2_036.jpg	Edgar Link	pending
ex2_037.jpg	Edgar Link	pending
ex2_038.jpg	Edgar Link	pending
ex2_039.jpg	Edgar Link	pending
ex2_040.jpg	Edgar Link	pending
ex2_041.jpg	Edgar Link	pending
ex2_042.jpg	Edgar Link	pending
ex2_043.jpg	Edgar Link	pending
ex2_044.jpg	Edgar Link	pending
ex2_045.jpg	Edgar Link	pending
ex2_046.jpg	Edgar Link	pending
ex2_047.jpg	Edgar Link	pending
ex2_048.jpg	Edgar Link	pending
ex2_049.jpg	Edgar Link	pending
ex2_050.jpg	Edgar Link	pending
ex2_051.jpg	Edgar Link	pending
ex2_052.jpg	Edgar Link	pending
ex2_053.jpg	Edgar Link	pending
ex2_054.jpg	Edgar Link	pending
ex2_055.jpg	Edgar Link	pending
ex2_056.jpg	Edgar Link	pending
ex2_057.jpg	Edgar Link	pending
ex2_058.jpg	Edgar Link	pending
ex2_059.jpg	Edgar Link	pending
ex2_060.jpg	Edgar Link	pending
ex2_061.jpg	Edgar Link	pending
ex2_062.jpg	Edgar Link	pending
ex2_063.jpg	Edgar Link	pending
ex2_064.jpg	Edgar Link	pending
ex2_065.jpg	Edgar Link	pending
ex2_066.jpg	Edgar Link	pending
ex2_067.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-15.htm	Edgar Link	pending
ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
form10-k_003.jpg	Edgar Link	pending
form10-k_004.jpg	Edgar Link	pending
form10-k_005.jpg	Edgar Link	pending
form10-k_006.jpg	Edgar Link	pending
form10-k_007.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
naov-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
naov-20231231_def.xml	Edgar Link	unprocessable
naov-20231231_lab.xml	Edgar Link	unprocessable
naov-20231231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
naov-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NAOV
NanoVibronix, Inc. Stock $naov

2024 Q2 Form 10-K Financial Statement

#000149315224013966 Filed on April 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NAOV NanoVibronix, Inc. Stock $naov

2024 Q2 Form 10-K Financial Statement

#000149315224013966 Filed on April 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NAOV
NanoVibronix, Inc. Stock $naov